Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 17% Improvement Relative Risk ICU admission 11% TFS score 30% c19early.com/aa Kotfis et al. NCT04912011 Potassium canrenoate RCT LATE Favors potassium canrenoate Favors control
Kotfis, 49 patient potassium canrenoate antiandrogen late treatment RCT: 17% lower mortality [p=1], 11% lower ICU admission [p=1], and 30% improved recovery [p=0.51] https://c19p.org/kotfis
copied to clipboard
Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial
Kotfis et al., Pharmaceuticals, doi:10.3390/ph15020200
5 Feb 2022    Source   PDF   Share   Tweet
RCT with 24 patients treated with potassium canrenoate and 25 placebo patients in Poland, showing no significant differences.
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 4 of 24 (16.7%), control 5 of 25 (20.0%), NNT 30.
risk of ICU admission, 10.7% lower, RR 0.89, p = 1.00, treatment 6 of 24 (25.0%), control 7 of 25 (28.0%), NNT 33.
relative TFS score, 30.4% better, RR 0.70, p = 0.51, treatment 24, control 25.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kotfis et al., 2/5/2022, Randomized Controlled Trial, placebo-controlled, Poland, Europe, peer-reviewed, 10 authors, study period December 2020 - August 2021, trial NCT04912011.
Contact: katarzyna.kotfis@pum.edu.pl (corresponding author), igor.karolak@gmail.com, kacper.lechowicz@gmail.com, mazegan@wp.pl, apikulska@wp.pl, paulina.niedzwiedzka-rystwej@usz.edu.pl, kawamilosz@gmail.com, jsien@poczta.onet.pl, aleksandra.szylinska@gmail.com, mwisniewska35@gmail.com.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit